Welcome to our dedicated page for Lucid Diagnostics SEC filings (Ticker: LUCD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Lucid Diagnostics Inc. (NASDAQ: LUCD), a commercial-stage, cancer prevention medical diagnostics company focused on esophageal precancer detection in patients with gastroesophageal reflux disease (GERD). Through these filings, investors can review the company’s official disclosures on financial performance, capital structure, and material corporate events.
Current reports on Form 8-K document significant events such as quarterly financial results, public offerings of common stock, and board appointments. For example, Lucid has filed 8-Ks to furnish press releases announcing financial results for quarters ended June 30 and September 30, 2025, to report the entry into and closing of an underwritten public offering of common stock under a shelf registration statement on Form S-3, and to disclose the appointment of a new director designated by holders of its convertible secured promissory notes.
Periodic reports such as Forms 10-Q and 10-K, referenced in Lucid’s press releases and 8-K filings, contain detailed financial statements, management’s discussion and analysis, and additional information about its EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device business. These documents explain how the company reports EsoGuard-related revenues, operating expenses, and non-GAAP measures such as EBITDA and non-GAAP adjusted loss.
Investors can also find information on securities offerings and agreements in Lucid’s filings. An 8-K dated September 10, 2025 describes an underwriting agreement for an underwritten public offering of common stock, including the number of shares, public offering price, underwriting discount, and use of proceeds for working capital and general corporate purposes. A subsequent 8-K dated September 11, 2025 reports the closing of that offering and the expected net proceeds.
Stock Titan’s interface surfaces these SEC filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the significance of each filing. Real-time updates from the EDGAR system ensure that new 8-Ks, 10-Qs, 10-Ks, and other forms are added as they are filed, while Form 4 and related insider transaction reports, when available, can be reviewed to analyze trading activity by Lucid’s officers, directors, or significant shareholders.
PALUMBO JOHN R reported acquisition or exercise transactions in this Form 4 filing.
Lucid Diagnostics Inc. director John R. Palumbo received a grant of 123,000 shares of common stock as a restricted stock award under the company’s 2018 Equity Plan. The award was granted at $0.00 per share and increases his directly held common stock to 338,000 shares.
The restricted stock has a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed, meaning Palumbo must remain in the specified service role through that date for the shares to fully vest.
Lapidus Stanley reported acquisition or exercise transactions in this Form 4 filing.
Lucid Diagnostics Inc. director Stanley Lapidus received a grant of 123,000 shares of common stock as an equity award. The award was granted at no cash cost and increased his directly held shares to 337,392. The shares are restricted stock under the company’s 2018 Equity Plan with a single vesting date of May 20, 2029, and are subject to forfeiture if the required service period is not completed.
Lucid Diagnostics Inc. director James L. Cox reported an equity award of common stock. He acquired 123,000 shares of restricted stock at a grant price of $0.00 per share as a grant, award, or other acquisition under the company’s 2018 Equity Plan. These restricted shares have a single vesting date of May 20, 2029 and are subject to forfeiture if the required service period is not completed. Following this award, Cox directly holds a total of 405,120 shares of Lucid Diagnostics common stock.
Lucid Diagnostics Inc. reported that Chief Financial Officer Dennis M. McGrath acquired 470,000 shares of common stock through a restricted stock grant at a price of $0.00 per share. These shares vest in a single installment on May 20, 2029 and are subject to forfeiture if the required service period is not completed. Following this award, McGrath directly holds 1,813,569 shares of Lucid Diagnostics common stock.
Lucid Diagnostics Inc. reported that President and COO Shaun O'Neil acquired 620,000 shares of common stock through a restricted stock grant under the company’s 2018 Equity Plan. The restricted stock has a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed. Following this award, O'Neil directly holds 1,446,763 shares of common stock.
Gordon Michael Adam reported acquisition or exercise transactions in this Form 4 filing.
Lucid Diagnostics Inc. reported that its General Counsel and Secretary, Gordon Michael Adam, received a grant of 300,000 shares of common stock on February 20, 2026. The award is structured as restricted stock that vests in full on May 20, 2029 and is subject to forfeiture if the required service period is not completed. Following this grant, Adam directly holds 1,000,000 shares of Lucid Diagnostics common stock.
PAVmed Inc. filed Amendment No. 6 to its Schedule 13D regarding its stake in Lucid Diagnostics Inc.. PAVmed reports beneficial ownership of 38,816,903 shares of Lucid common stock, representing 27.5% of the class, giving it significant influence over shareholder votes.
The filing notes sole voting power over 38,816,903 shares and sole dispositive power over 31,302,444 shares, including voting proxies obtained from other Lucid stockholders and officers. PAVmed also entered an Amendment Agreement granting its noteholder the right to receive 300,000 Lucid shares upon specified future events, subject to a beneficial ownership limitation.
Lucid Diagnostics (LUCD) furnished an update announcing it issued a press release with financial results for the fiscal quarter ended September 30, 2025 and a business update. The release was provided as Exhibit 99.1. The information was furnished under Items 2.02 and 7.01 and is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference unless specifically stated.
Lucid Diagnostics (LUCD) reported Q3 2025 results, highlighting modest revenue and continued investment alongside a formal going concern warning. Revenue was $1.2 million for the quarter and $3.2 million year-to-date, reflecting ongoing early commercialization of EsoGuard testing. Operating loss was $11.8 million in Q3; net loss attributable to common stockholders was $10.4 million, or $0.10 per share.
Cash stood at $47.3 million as of September 30, 2025, with working capital of $23.6 million and operating cash outflows of $33.9 million for the nine months. Management states that substantial doubt exists about the company’s ability to continue as a going concern within one year, absent materially higher reimbursement-driven revenue or additional financing.
To fund operations, Lucid raised capital through equity offerings—$14.9 million (March), $16.2 million (April), and $27.0 million (September)—and has $21.975 million face value of 12% Senior Secured Convertible Notes (fair value $22.3 million; $1.00 conversion price). Common shares issued and outstanding were 130,924,686 as of September 30, 2025; 137,683,002 as of November 7, 2025.
PAVmed Inc. filed Amendment No. 5 to its Schedule 13D on Lucid Diagnostics (LUCD), reporting significant ownership and updated voting arrangements. PAVmed beneficially owns 38,816,903 shares of common stock, representing 28.3% of the class. It reports sole voting power over 38,816,903 shares and sole dispositive power over 31,302,444 shares.
On October 9, 2025, PAVmed entered a new Voting Agreement covering shares representing 3,177,500 votes of common stock and 3,862,911 votes of other capital stock, in addition to prior voting agreements covering 4,336,959 votes held by certain officers. Recent insider-related activity includes restricted stock awards granted on February 20, 2025 to officers (300,000 shares each) and directors (112,800 shares each), and an open-market purchase by a trust controlled by Michael J. Glennon of 129,000 shares at approximately $1.04 per share for an aggregate of $133,782.70. Certain insiders agreed to a 45‑day lockup in connection with the September 10, 2025 underwritten offering.